Trius Therapeutics, Inc
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.
They are currently conducting Phase 3 trials for torezolid phosphate (TR-701), an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.
Contact Details
Office Address
Trius Therapeutics, Inc
6310 Nancy Ridge Dr., Ste. 101
San Diego, CA, USA 92121
Phone: (858) 452-0370
Fax: (858) 677-9975
Executives
Chairman
David S. Kabakoff
President, CEO, and Director
Jeffrey Stein
.webp)
.webp)
.webp)
.webp)
.webp)
